Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 1,370,000 shares, a decline of 21.3% from the January 15th total of 1,740,000 shares. Based on an average trading volume of 3,200,000 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of Aethlon Medical in a research report on Monday, January 27th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research report on Thursday, January 30th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC bought a new position in shares of Aethlon Medical during the fourth quarter worth approximately $186,000. Sassicaia Capital Advisers LLC bought a new position in shares of Aethlon Medical during the fourth quarter worth approximately $31,000. Renaissance Technologies LLC bought a new position in shares of Aethlon Medical during the fourth quarter worth approximately $25,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical during the fourth quarter worth approximately $81,000. Finally, Allegiance Financial Group Advisory Services LLC bought a new position in shares of Aethlon Medical during the fourth quarter worth approximately $26,000. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $0.62 on Friday. Aethlon Medical has a one year low of $0.24 and a one year high of $1.85. The company has a market cap of $8.59 million, a price-to-earnings ratio of -0.22 and a beta of 1.88. The firm has a 50-day moving average of $0.63 and a 200-day moving average of $0.48.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.09. As a group, sell-side analysts expect that Aethlon Medical will post -1.01 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.